LFB links with Japanese firm for controlled release Factor VII
This article was originally published in Scrip
Executive Summary
The French state-owned company LFB Biotechnologies has entered into an option agreement to apply delivery technology developed by Japan's NanoCarrier to a recombinant Factor VIIa product for haemophilia patients.